Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02901054 · ClinicalTrials.gov registry record · NA
CSF Pharmacokinetics of Ondansetron
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02901054 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 19 participants.
The verdict
NCT02901054, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
Serotonergic 5-HT3 receptors in the central nervous system are involved in pain processing after nerve injury. We are interested in learning if 5-HT3 receptor antagonist ondansetron might be an appropriate drug for treating pain after nerve injury (neuropathic pain), by investigating its bio-distribution in the cerebro-spinal fluid, and the genetic variability that may affect that distribution. Study procedures will include iv ondansetron administration, serial blood draws, cerebrospinal fluid (CSF) sampling, pregnancy testing, and possible ECG.
Interventions
- DRUG Ondansetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-08-25 |
| Est. Completion | 2016-11-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02901054
The ClinicalTrials.gov registry entry for NCT02901054 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ondansetron is the first listed.
NCT02901054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02901054 about?
NCT02901054 is a clinical study titled "CSF Pharmacokinetics of Ondansetron". Serotonergic 5-HT3 receptors in the central nervous system are involved in pain processing after nerve injury. We are interested in learning if 5-HT3 receptor antagonist ondansetron might be an appropriate drug for treating pain after nerve injury (neuropathic pain), by investigating its bio-distrib...
What is the current status of trial NCT02901054?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2016-08-25. Estimated completion is 2016-11-17.
What interventions are being tested in trial NCT02901054?
The interventions under investigation include: Ondansetron (DRUG).
Who is sponsoring clinical trial NCT02901054?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.